United Therapeutics (UTHR) Insider Sale — 700 Shares Disposed

Rhea-AI Filing Summary

Malcolm Jan, a director of United Therapeutics Corp (UTHR), reported a single transaction disposing of 700 shares of the issuer's common stock on 09/09/2025 at a reported price of $400.29 per share. After this sale the filing shows 520 shares beneficially owned by Mr. Jan in a direct ownership form. The Form 4 was filed as a single reporting person disclosure and identifies the reporting relationship as Director.

Insights

Securities Analyst

TL;DR: Routine insider sale reported; transaction details are explicit and limited to one disposition of 700 shares at $400.29.

This Form 4 documents a single sale by a director with the reporting person retaining 520 shares after the transaction. There are no derivative transactions or additional issuances reported. The disclosure provides clear, standard Section 16 reporting of an insider sale without further context on intent or larger trading programs.

Corporate Governance Expert

TL;DR: Routine director sale disclosed; the filing is procedural and contains no governance irregularities or multiple-party reporting.

The form identifies the filer as a director and shows the sale was reported by one reporting person. The filing was signed under a power of attorney, which is a common administrative practice. No option exercises, grants, or indirect ownership changes are reported, limiting material governance implications.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MALCOLM JAN

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MD 20910

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/09/2025		S		700	D	$400.29	520	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	09/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Malcolm Jan report on Form 4 for UTHR?

The Form 4 reports a sale of 700 shares of United Therapeutics common stock executed on 09/09/2025 at a price of $400.29 per share.

How many UTHR shares does the reporting person own after the reported transaction?

Following the reported sale the filing shows 520 shares beneficially owned by the reporting person in a direct ownership form.

What is the reporting person's relationship to United Therapeutics (UTHR)?

The report identifies the reporting person, Malcolm Jan, as a Director of United Therapeutics Corporation.

Were any derivative securities, option exercises, or acquisitions reported in this Form 4 for UTHR?

No. Table II for derivative securities is empty and the filing lists only a single non-derivative disposition (sale) of common stock.

Was this Form 4 filed by more than one reporting person?

No. The filing indicates it was submitted as a Form filed by one reporting person.